The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs
after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the
decision to continue/discontinue statins should be influenced by an individual's
Apolipoprotein-E (APOE) genotype.
Phase:
Phase 3
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Canadian Stroke Consortium (CSC) Medical University of South Carolina NIH/NINDS StrokeNet NINDS Stroke Trials Network (StrokeNet) University of Cincinnati